Cargando…

Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection

We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Eik, Scheer, Christian, Saljé, Karen, Fritz, Anja, Kohlmann, Thomas, Hübner, Nils-Olaf, Napp, Matthias, Fiedler-Lacombe, Lizon, Stahl, Dana, Rauch, Bernhard, Nauck, Matthias, Völker, Uwe, Felix, Stephan, Lucchese, Guglielmo, Flöel, Agnes, Engeli, Stefan, Hoffmann, Wolfgang, Hahnenkamp, Klaus, Tzvetkov, Mladen V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065670/
https://www.ncbi.nlm.nih.gov/pubmed/35508524
http://dx.doi.org/10.1038/s41598-022-11103-0
_version_ 1784699635331235840
author Schäfer, Eik
Scheer, Christian
Saljé, Karen
Fritz, Anja
Kohlmann, Thomas
Hübner, Nils-Olaf
Napp, Matthias
Fiedler-Lacombe, Lizon
Stahl, Dana
Rauch, Bernhard
Nauck, Matthias
Völker, Uwe
Felix, Stephan
Lucchese, Guglielmo
Flöel, Agnes
Engeli, Stefan
Hoffmann, Wolfgang
Hahnenkamp, Klaus
Tzvetkov, Mladen V.
author_facet Schäfer, Eik
Scheer, Christian
Saljé, Karen
Fritz, Anja
Kohlmann, Thomas
Hübner, Nils-Olaf
Napp, Matthias
Fiedler-Lacombe, Lizon
Stahl, Dana
Rauch, Bernhard
Nauck, Matthias
Völker, Uwe
Felix, Stephan
Lucchese, Guglielmo
Flöel, Agnes
Engeli, Stefan
Hoffmann, Wolfgang
Hahnenkamp, Klaus
Tzvetkov, Mladen V.
author_sort Schäfer, Eik
collection PubMed
description We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.
format Online
Article
Text
id pubmed-9065670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90656702022-05-04 Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection Schäfer, Eik Scheer, Christian Saljé, Karen Fritz, Anja Kohlmann, Thomas Hübner, Nils-Olaf Napp, Matthias Fiedler-Lacombe, Lizon Stahl, Dana Rauch, Bernhard Nauck, Matthias Völker, Uwe Felix, Stephan Lucchese, Guglielmo Flöel, Agnes Engeli, Stefan Hoffmann, Wolfgang Hahnenkamp, Klaus Tzvetkov, Mladen V. Sci Rep Article We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization. Nature Publishing Group UK 2022-05-04 /pmc/articles/PMC9065670/ /pubmed/35508524 http://dx.doi.org/10.1038/s41598-022-11103-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Schäfer, Eik
Scheer, Christian
Saljé, Karen
Fritz, Anja
Kohlmann, Thomas
Hübner, Nils-Olaf
Napp, Matthias
Fiedler-Lacombe, Lizon
Stahl, Dana
Rauch, Bernhard
Nauck, Matthias
Völker, Uwe
Felix, Stephan
Lucchese, Guglielmo
Flöel, Agnes
Engeli, Stefan
Hoffmann, Wolfgang
Hahnenkamp, Klaus
Tzvetkov, Mladen V.
Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title_full Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title_fullStr Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title_full_unstemmed Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title_short Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
title_sort course of disease and risk factors for hospitalization in outpatients with a sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065670/
https://www.ncbi.nlm.nih.gov/pubmed/35508524
http://dx.doi.org/10.1038/s41598-022-11103-0
work_keys_str_mv AT schafereik courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT scheerchristian courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT saljekaren courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT fritzanja courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT kohlmannthomas courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT hubnernilsolaf courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT nappmatthias courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT fiedlerlacombelizon courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT stahldana courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT rauchbernhard courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT nauckmatthias courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT volkeruwe courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT felixstephan courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT luccheseguglielmo courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT floelagnes courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT engelistefan courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT hoffmannwolfgang courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT hahnenkampklaus courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection
AT tzvetkovmladenv courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection